The company started in 2014, based on the discoveries made in the Xiao group, about the enantioselective reduction of pyridines to the corresponding chiral piperdines.
The Xiao group rapidly realised the potential of these researches, as many marketed drugs contain substituted piperidine rings. These initial discoveries led to the formation of LCC.
Since then, we’ve enhanced the scope of our expertise to provide leading scientific organisations around the world with access to chirally-pure compounds that play their part in small molecule drug discovery.